Pure Biologics Spólka Akcyjna
PUR.WA · WSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | -0.01 | 0.13 | -0.00 |
| FCF Yield | -0.61% | -0.88% | -1.36% | -4.15% |
| EV / EBITDA | -59.41 | -15.85 | -96.65 | -15.93 |
| Quality | ||||
| ROIC | 20.48% | 79.65% | -82.56% | -728.18% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.17 | 0.04 | 0.59 | 0.37 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | – | -100.00% |
| Free Cash Flow Growth | -17.39% | 76.56% | 80.04% | -131.29% |
| Safety | ||||
| Net Debt / EBITDA | -17.48 | -6.48 | -19.13 | -2.02 |
| Interest Coverage | -2.30 | -5.73 | -2.68 | -18.04 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -46,224.00 | -19,102.50 | -12,285.00 | -7,659.00 |